SPIE Quantum West to Showcase High-Profile Industry Voices
2.2.2021 20:03:00 EET | Business Wire | Press release
SPIE, the international society for optics and photonics, announces the program for its inaugural industry-focused SPIE Quantum West conference 6-11 March. Organized in partnership with the Quantum Economic Development Consortium (QED-C), Quantum West will be held online during the SPIE Photonics West Digital Forum.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005101/en/
Attendance at Quantum West is free to all registered participants of SPIE Photonics West, but registration is required.
The four sessions will provide a wide range of opportunities to learn more about the role of photonics in the development of quantum technology as quantum moves from research and development to engineering products for the commercial marketplace, while building mainstream infrastructures and supply chains. Speakers’ topics include “Quantum Technology as an Enabler,” “Photonics’ Roles in Superconducting Quantum Computing,” and “Building an Industry: Lessons Learned from a Half-Century of Growth in the Photonics Industry.” The four-day event, co-hosted by QED-C Deputy Director Celia Merzbacher and ColdQuanta Executive Chairman and DRS Daylight Solutions Senior Vice President Tim Day, will also include a market report from the Boston Consulting Group.
The international slate of speakers includes Imperial College London’s Peter Knight, who is also a member of the UK’s Quantum Technology Strategic Advisory Board; Andrew Lord, who heads British Telecom’s optical core, access, and quantum research; Google Product Manager Eric Ostby; Toptica’s co-founder and CTO Wilhelm G. Kaenders; Kaitlin R. Moore, a research physicist and principal investigator with SRI International; and Mercedes Gimeno-Segovia, senior director of quantum architecture at PsiQuantum.
A panel discussion on the final day featuring Toptica’s Mark Tolbert, IBM’s Jason Orcutt, Anchored In’s Anke Lohman, and Hamamatsu’s Klea Dhimitri, and moderated by Tim Day, will explore the future of photonics and quantum (“2021 and Beyond”), the challenges of developing a new market, and how photonics will support that.
“We are delighted to partner with the QED-C in launching the first annual Quantum West event,” said SPIE Director of Industry Development Stephen Anderson. “As one of the few industry-oriented quantum technology events to focus on the role of optics and photonics in the emerging market for quantum-enabled devices, Quantum West will play a key role in showcasing the future of the quantum industry and the opportunities it presents for photonics technologies."
“Optics and photonics are critical enabling technologies for many quantum-based applications, including for sensing, communications and computing,” noted QED-C’s Merzbacher. “Quantum West will bring together the photonics and quantum communities to help build the ecosystem and supply chain for the emerging quantum industry.”
To find out more about Quantum West and to register for the event, visit the SPIE Quantum West page.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5.8 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org.
About Quantum Economic Development Consortium:
The Quantum Economic Development Consortium (QED-C) is an industry-driven consortium managed by SRI International and established in response to the 2018 National Quantum Initiative Act. Membership includes more than 120 US companies from across the supply chain and more than 40 academic institutions and other stakeholders. The consortium seeks to enable and grow the quantum industry and associated supply chain. For more about QED-C, visit our website or follow us on Twitter @The_QEDC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005101/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom